Haemophilus Influenzae Type b Vaccine
Haemophilus Influenzae Type b Vaccine Information

About Haemophilus Influenzae Type b Vaccine

Haemophilus Influenzae Type b Vaccine is a liquid or freez dried preparation of a polysaccharide, polyribosylribitol phosphate (PRP), derived from a suitable strain of Haemophilus influenza type b, covalently bound to a carrier protein. The immunogenicity, especially in young children, has been shown to be improved by linking the polysaccharides to a protein carrier such as diphtheria toxin or tetanus toxoid to form a conjugate vaccine. for active immunisation against Haemophilus influenzaetype b infections, among the major causes of meningitis and other esvere systemic illness in young children.

Indications

Haemophilus Influenzae Type b Vaccine is primarily indicated in conditions like Haemophilus influenza type b infection.

Contraindication

Haemophilus Influenzae Type b Vaccine is contraindicated in conditions like Hypersensitivity,Severe febrile illness.

Side Effects

The severe or irreversible adverse effects of Haemophilus Influenzae Type b Vaccine, which give rise to further complications include Allergic reactions.Haemophilus Influenzae Type b Vaccine produces potentially life-threatening effects which include Anaphylactoid reactions. which are responsible for the discontinuation of Haemophilus Influenzae Type b Vaccine therapy.The symptomatic adverse reactions produced by Haemophilus Influenzae Type b Vaccine are more or less tolerable and if they become severe, they can be treated symptomatically, these include Vomiting, Diarrhea, Fever, Restlessness, Redness, Swelling at injection site, Unusual crying, Loss of appetite, Pain at injection site.

Warnings

It should be used with caution in patients with a history of haemophilus influenza type b hypersensitivity, tetanus toxoid hypersensitivity, Neisseria meningitidis hypersensitivity or diphtheria toxoid hypersensitivity because antigens related to these products are used in haemophilus influenza vaccine. Vaccination with haemophilus influenza type b alone does not substitute for routine tetanus vaccination. Antigen detection does not have a diagnostic value in suspected Hib disease within 1-2 weeks of vaccination. Medical care must be available in case of rare anaphylactic reactions. In subjects who have received human gammaglobulins or a blood transfusion vaccination should be delayed for atleast three months .Different injectable vaccine should be administered at different injection site.

High Risk Groups

If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.